Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther October 1 2011 10 (10) 1761-1761;

Review

  • Review
    Targeting Axl and Mer Kinases in Cancer
    Anupam Verma, Steven L. Warner, Hariprasad Vankayalapati, David J. Bearss and Sunil Sharma
    Mol Cancer Ther October 1 2011 10 (10) 1763-1773; DOI:10.1158/1535-7163.MCT-11-0116

Therapeutic Discovery

  • Therapeutic Discovery
    Identification of a Natural Compound by Cell-Based Screening That Enhances Interferon Regulatory Factor-1 Activity and Causes Tumor Suppression
    Jinbo Gao, Yujun Wang, Quanhua Xing, Jin Yan, Maheswari Senthil, Yasir Akmal, Claudia M. Kowolik, Julia Kang, David M. Lu, Ming Zhao, Zhixiu Lin, Christopher H.K. Cheng, M.L. Richard Yip and John H. Yim
    Mol Cancer Ther October 1 2011 10 (10) 1774-1783; DOI:10.1158/1535-7163.MCT-11-0304

  • Therapeutic Discovery
    Telomere Targeting with a New G4 Ligand Enhances Radiation-Induced Killing of Human Glioblastoma Cells
    Patrick Merle, Bertrand Evrard, Anne Petitjean, Jean-Marie Lehn, Marie-Paule Teulade-Fichou, Emmanuel Chautard, Anne De Cian, Lionel Guittat, Phong Lan Thao Tran, Jean-Louis Mergny, Pierre Verrelle and Andreï Tchirkov
    Mol Cancer Ther October 1 2011 10 (10) 1784-1795; DOI:10.1158/1535-7163.MCT-10-0664

  • Therapeutic Discovery
    Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin
    Tracy M. Neher, Diane Bodenmiller, Richard W. Fitch, Shadia I. Jalal and John J. Turchi
    Mol Cancer Ther October 1 2011 10 (10) 1796-1806; DOI:10.1158/1535-7163.MCT-11-0303

  • Therapeutic Discovery
    A Novel Kinase Inhibitor of FADD Phosphorylation Chemosensitizes through the Inhibition of NF-κB
    Katrina A. Schinske, Shyam Nyati, Amjad P. Khan, Terence M. Williams, Timothy D. Johnson, Brian D. Ross, Ricardo Pérez Tomás and Alnawaz Rehemtulla
    Mol Cancer Ther October 1 2011 10 (10) 1807-1817; DOI:10.1158/1535-7163.MCT-11-0362

  • Therapeutic Discovery
    A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells
    Koppany Visnyei, Hideyuki Onodera, Robert Damoiseaux, Kuniyasu Saigusa, Syuzanna Petrosyan, David De Vries, Denise Ferrari, Jonathan Saxe, Eduard H. Panosyan, Michael Masterman-Smith, Jack Mottahedeh, Kenneth A. Bradley, Jing Huang, Chiara Sabatti, Ichiro Nakano and Harley I. Kornblum
    Mol Cancer Ther October 1 2011 10 (10) 1818-1828; DOI:10.1158/1535-7163.MCT-11-0268

  • Therapeutic Discovery
    Targeting Tumor-Initiating Cancer Cells with dCD133KDEL Shows Impressive Tumor Reductions in a Xenotransplant Model of Human Head and Neck Cancer
    Nate N. Waldron, Dan S. Kaufman, Seunguk Oh, Zintis Inde, Melinda K. Hexum, John R. Ohlfest and Daniel A. Vallera
    Mol Cancer Ther October 1 2011 10 (10) 1829-1838; DOI:10.1158/1535-7163.MCT-11-0206

  • Therapeutic Discovery
    Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines
    Venita Gresham Watson, Nicholas E. Hardison, Tyndall Harris, Alison Motsinger-Reif and Howard L. McLeod
    Mol Cancer Ther October 1 2011 10 (10) 1839-1845; DOI:10.1158/1535-7163.MCT-10-0872

  • Therapeutic Discovery
    An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
    Georg E. Winter, Uwe Rix, Andrej Lissat, Alexey Stukalov, Markus K. Müllner, Keiryn L. Bennett, Jacques Colinge, Sebastian M. Nijman, Stefan Kubicek, Heinrich Kovar, Udo Kontny and Giulio Superti-Furga
    Mol Cancer Ther October 1 2011 10 (10) 1846-1856; DOI:10.1158/1535-7163.MCT-11-0100

  • Therapeutic Discovery
    Prioritizing Candidate Disease miRNAs by Topological Features in the miRNA Target–Dysregulated Network: Case Study of Prostate Cancer
    Juan Xu, Chuan-Xing Li, Jun-Ying Lv, Yong-Sheng Li, Yun Xiao, Ting-Ting Shao, Xiao Huo, Xiang Li, Yan Zou, Qing-Lian Han, Xia Li, Li-Hua Wang and Huan Ren
    Mol Cancer Ther October 1 2011 10 (10) 1857-1866; DOI:10.1158/1535-7163.MCT-11-0055

Preclinical Development

  • Preclinical Development
    NF-κB Is Required for Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for γ-Irradiation–Induced Apoptosis
    Rebecca Berger, Claudia Jennewein, Viola Marschall, Sabine Karl, Silvia Cristofanon, Liane Wagner, Sri HariKrishna Vellanki, Stephanie Hehlgans, Franz Rödel, Klaus-Michael Debatin, Albert C. Ludolph and Simone Fulda
    Mol Cancer Ther October 1 2011 10 (10) 1867-1875; DOI:10.1158/1535-7163.MCT-11-0218

  • Preclinical Development
    ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer
    Nicole Campbell, James Greenaway, Jack Henkin and Jim Petrik
    Mol Cancer Ther October 1 2011 10 (10) 1876-1885; DOI:10.1158/1535-7163.MCT-11-0402

  • Preclinical Development
    Targeting the Microtubular Network as a New Antimyeloma Strategy
    Rentian Feng, Shirong Li, Caisheng Lu, Carrie Andreas, Donna B. Stolz, Markus Y. Mapara and Suzanne Lentzsch
    Mol Cancer Ther October 1 2011 10 (10) 1886-1896; DOI:10.1158/1535-7163.MCT-11-0234

  • Preclinical Development
    The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors
    Giuseppe Floris, Maria Debiec-Rychter, Agnieszka Wozniak, Cristiana Stefan, Emmanuel Normant, Gavino Faa, Kathleen Machiels, Ulla Vanleeuw, Raf Sciot and Patrick Schöffski
    Mol Cancer Ther October 1 2011 10 (10) 1897-1908; DOI:10.1158/1535-7163.MCT-11-0148

  • Preclinical Development
    Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma
    Tiffany Khong and Andrew Spencer
    Mol Cancer Ther October 1 2011 10 (10) 1909-1917; DOI:10.1158/1535-7163.MCT-11-0174

  • Preclinical Development
    Tumor-Specific Targeting of Pancreatic Cancer with Shiga Toxin B-Subunit
    Matthias Maak, Ulrich Nitsche, Larissa Keller, Petra Wolf, Marianne Sarr, Marine Thiebaud, Robert Rosenberg, Rupert Langer, Jörg Kleeff, Helmut Friess, Ludger Johannes and Klaus-Peter Janssen
    Mol Cancer Ther October 1 2011 10 (10) 1918-1928; DOI:10.1158/1535-7163.MCT-11-0006

  • Preclinical Development
    CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin
    Naoki Mine, Sayaka Yamamoto, Naoya Saito, Satoshi Yamazaki, Chikako Suda, Machiyo Ishigaki, Donald W. Kufe, Daniel D. Von Hoff and Takumi Kawabe
    Mol Cancer Ther October 1 2011 10 (10) 1929-1938; DOI:10.1158/1535-7163.MCT-10-1139

  • Preclinical Development
    Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents
    Thapi D. Rao, Nestor Rosales and David R. Spriggs
    Mol Cancer Ther October 1 2011 10 (10) 1939-1948; DOI:10.1158/1535-7163.MCT-11-0228

  • Preclinical Development
    Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
    Joana M. Senra, Brian A. Telfer, Kim E. Cherry, Cian M. McCrudden, David G. Hirst, Mark J. O'Connor, Stephen R. Wedge and Ian J. Stratford
    Mol Cancer Ther October 1 2011 10 (10) 1949-1958; DOI:10.1158/1535-7163.MCT-11-0278

  • Preclinical Development
    Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models
    Rachel M. Squillace, David Miller, Michelle Cookson, Scott D. Wardwell, Lauren Moran, David Clapham, Frank Wang, Tim Clackson and Victor M. Rivera
    Mol Cancer Ther October 1 2011 10 (10) 1959-1968; DOI:10.1158/1535-7163.MCT-11-0273

  • Preclinical Development
    2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression
    Carmine Stolfi, Roberta Caruso, Eleonora Franzè, Angelamaria Rizzo, Angela Rotondi, Ivan Monteleone, Massimo Claudio Fantini, Francesco Pallone and Giovanni Monteleone
    Mol Cancer Ther October 1 2011 10 (10) 1969-1981; DOI:10.1158/1535-7163.MCT-11-0316

  • Preclinical Development
    CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells
    Boon Shing Tan, Kai Hung Tiong, Ashwin Muruhadas, Nirmal Randhawa, Heng Lungh Choo, Tracey D. Bradshaw, Malcolm F.G. Stevens and Chee-Onn Leong
    Mol Cancer Ther October 1 2011 10 (10) 1982-1992; DOI:10.1158/1535-7163.MCT-11-0391

Molecular Medicine in Practice

  • Molecular Medicine in Practice
    Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy
    Seung Tae Kim, Do Hyoung Lim, Kee-Taek Jang, Taekyu Lim, Jeeyun Lee, Yoon-La Choi, Hye-Lim Jang, Jun Ho Yi, Kyung Kee Baek, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang and Joon Oh Park
    Mol Cancer Ther October 1 2011 10 (10) 1993-1999; DOI:10.1158/1535-7163.MCT-11-0269

  • Molecular Medicine in Practice | Free Article
    BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
    Tamar Safra, Lucia Borgato, Maria Ornella Nicoletto, Linda Rolnitzky, Sharon Pelles-Avraham, Ravit Geva, Martin Edward Donach, John Curtin, Akiva Novetsky, Tal Grenader, Wei-Chu V. Lai, Alberto Gabizon, Leslie Boyd and Franco Muggia
    Mol Cancer Ther October 1 2011 10 (10) 2000-2007; DOI:10.1158/1535-7163.MCT-11-0272

Back to top
PreviousNext
Molecular Cancer Therapeutics: 10 (10)
October 2011
Volume 10, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • Targeting Axl and Mer Kinases in Cancer
  • BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
  • Prioritizing Candidate Disease miRNAs by Topological Features in the miRNA Target–Dysregulated Network: Case Study of Prostate Cancer
  • ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer

Jump to

  • Highlights
  • Review
  • Therapeutic Discovery
  • Preclinical Development
  • Molecular Medicine in Practice
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement